Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 342

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials

Shelley, M.D., Wilt, T.J., Court, J., Coles, B., Kynaston, H., Mason, M.D.·2004·BJU International

Abstract

The first paper in this section is a meta‐analysis of randomized trials into the effect of two intravesical agents used to reduce tumour recurrence in high‐risk superficial bladder cancer. This is the highest level of evidence‐based medicine and the results presented here suggest that intravesical BCG is superior to mitomycin C. There was no difference in the effect of the two agents on disease progression or survival. In a study from Amsterdam and Rome, the authors describe a phase I trial into the toxicity and safety of intravesical gemcitabine, and found that it was well tolerated with no systemic toxicity. In a paper from Taiwan the link between viral infections and tumour foundation is evaluated, in this case specifically infections with the Epstein‐Barr virus and its correlation with urothelial cancer. The authors found that there was indeed a strong association between infection with this virus and a considerable proportion of primary urothelial TCCs. OBJECTIVE: To assess, in a systematic review and meta‐analysis, the relative effectiveness of intravesical mitomycin C and bacillus Calmette‐Guérin (BCG) for tumour recurrence, disease progression and overall survival in patients with medium‐ to high‐risk Ta and T1 bladder cancer. METHODS: The major medical databases were searched comprehensively up to June 2003, and relevant journals hand‐searched for randomized controlled trials, in any language, that compared intravesical mitomycin C with BCG in medium‐ to high‐risk patients with Ta or T1 bladder cancer. RESULTS: Twenty‐five articles were identified but only seven were considered eligible for the analysis. This represented 1901 evaluable patients in all, 820 randomized to mitomycin C and 1081 to BCG. Six trials had sufficient data for meta‐analysis and included 1527 patients, 693 in the mitomycin and 834 in the BCG arm. There was no significant difference between mitomycin C and BCG for tumour recurrence in the six trials, with a weighted mean log hazard ratio, LHR, (variance) of −0.022 (0.005). However, there was significant heterogeneity between trials ( P = 0.001). A subgroup analysis of three trials that included only high‐risk Ta and T1 patients indicated no heterogeneity ( P = 0.25) and a LHR for recurrence of −0.371 (0.012). With mitomycin C used as the control in the meta‐analysis, a negative ratio is in favour of BCG and, in this case, was highly significant ( P < 0.001). The seventh trial (in abstract form only) used BCG in low doses for two arms of the trial (27 mg and 13.5 mg) compared with a standard dose of mitomycin C (30 mg), and reported a significantly lower recurrence rate with BCG (27 mg) than for mitomycin C ( P = 0.001). Only two trials included sufficient data to analyse disease progression and survival, representing 681 patients (338 randomized to BCG and 343 to mitomycin C). There was no significant difference between mitomycin C and BCG for disease progression, with a LHR of 0.044 (0.04) ( P = 0.16), or survival, at −0.112 (0.03) ( P = 0.50). Adverse events were slightly more frequent with BCG. Local toxicity (dysuria, cystitis, frequency and haematuria) were associated with both mitomycin C (30%) and BCG (44%). Systemic toxicity, e.g. chills, fever and malaise, occurred with both agents (12% and 19%, respectively) although skin rash was more common with mitomycin C. CONCLUSION: Tumour recurrence was significantly lower with intravesical BCG than with mitomycin C only in those patients at high risk of tumour recurrence. However, there was no difference in disease progression or survival, and the decision to use either agent might be based on adverse events and cost.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-410x.2003.04655.x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 342

Metadata

Authors
Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D.
Venue
BJU International
Publisher
Wiley
Published
2004-02-20
Volume
93
Issue
4
Pages
485-490
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W2147633207
Cited by
342
References
17
FWCI
12.72
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials. https://app.cochat.ai/papers/10.1111/j.1464-410x.2003.04655.x
The paper
Shelley, M. D., Wilt, T. J., Court, J., Coles, B., Kynaston, H., & Mason, M. D. (2004). Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials. BJU International. https://doi.org/10.1111/j.1464-410x.2003.04655.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.